These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 9801337)
1. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Narita M; Matsuzono Y; Takekoshi Y; Yamada S; Itakura O; Kubota M; Kikuta H; Togashi T Clin Diagn Lab Immunol; 1998 Nov; 5(6):799-803. PubMed ID: 9801337 [TBL] [Abstract][Full Text] [Related]
2. [The benefit from mumps virus IgG antibody avidity testing in the population with high vaccine coverage in the context of other serological methods for laboratory diagnosis of mumps and the current epidemiological]. Limberková R; Smíšková D; Havlíčková M; Herrmannová K; Lexová P; Marešová V Epidemiol Mikrobiol Imunol; 2016; 65(1):39-44. PubMed ID: 27246643 [TBL] [Abstract][Full Text] [Related]
3. [Functional state of specific immunity in children and teenagers vaccinated against mumps]. Otrashevskaia EV; Bukin EK; Krasil'nikov IV; Ignat'ev GM Vopr Virusol; 2010; 55(4):20-5. PubMed ID: 20886708 [TBL] [Abstract][Full Text] [Related]
5. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Sanz-Moreno JC; Limia-Sánchez A; García-Comas L; Mosquera-Gutiérrez MM; Echevarria-Mayo JE; Castellanos-Nadal A; de Ory-Manchón F Vaccine; 2005 Sep; 23(41):4921-5. PubMed ID: 15996797 [TBL] [Abstract][Full Text] [Related]
6. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Park DW; Nam MH; Kim JY; Kim HJ; Sohn JW; Cho Y; Song KJ; Kim MJ Vaccine; 2007 Jun; 25(24):4665-70. PubMed ID: 17498856 [TBL] [Abstract][Full Text] [Related]
7. Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection. Mercader S; McGrew M; Sowers SB; Williams NJ; Bellini WJ; Hickman CJ mSphere; 2018 Sep; 3(5):. PubMed ID: 30209129 [TBL] [Abstract][Full Text] [Related]
8. [Virus strain specific serum neutralizing antibodies in children and adolescents immunized with a Russian mumps vaccine]. Otrashevskaia EV; Krasil'nikov IV; Ignat'ev GM Vopr Virusol; 2010; 55(6):15-9. PubMed ID: 21381334 [TBL] [Abstract][Full Text] [Related]
9. [Laboratory diagnosis of parotitis in the post-vaccination era]. de la Loma A; Villota J; Varela JM; Alonso M; de Ory F Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):119-20. PubMed ID: 12586040 [No Abstract] [Full Text] [Related]
10. Virus genotypes and responses of serum-specific antibodies in children with primary mumps and mumps reinfection. Sakata R; Nagita A; Kidokoro M; Kato A; Ogino K Pediatr Res; 2015 Nov; 78(5):580-4. PubMed ID: 26267156 [TBL] [Abstract][Full Text] [Related]
11. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Atrasheuskaya AV; Neverov AA; Rubin S; Ignatyev GM Vaccine; 2006 Mar; 24(10):1530-6. PubMed ID: 16266774 [TBL] [Abstract][Full Text] [Related]
12. Assessment of one-dose mumps-containing vaccine effectiveness on wild-type genotype F mumps viruses circulating in mainland China. Cui A; Zhu Z; Mao N; Si Y; Ma Y; Hu Y; Deng X; Wang L; Zeng L; Zhang Y; Xu W Vaccine; 2018 Sep; 36(38):5725-5731. PubMed ID: 30122648 [TBL] [Abstract][Full Text] [Related]
13. Determination of vaccine-induced and naturally acquired class-specific mumps antibodies by two indirect enzyme-linked immunosorbent assays. Nigro G; Nanni F; Midulla M J Virol Methods; 1986 May; 13(2):91-106. PubMed ID: 3016017 [TBL] [Abstract][Full Text] [Related]
14. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673 [TBL] [Abstract][Full Text] [Related]
15. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Paunio M; Hedman K; Davidkin I; Valle M; Heinonen OP; Leinikki P; Salmi A; Peltola H Epidemiol Infect; 2000 Apr; 124(2):263-71. PubMed ID: 10813152 [TBL] [Abstract][Full Text] [Related]
16. [Contribution of the detection of IgA antibodies to the laboratory diagnosis of mumps in the population with a high vaccination coverage]. Limberková R; Smíšková D; Havlíčková M; Herrmannová K; Lexová P; Malý M Epidemiol Mikrobiol Imunol; 2015 Mar; 64(1):16-9. PubMed ID: 25872991 [TBL] [Abstract][Full Text] [Related]
17. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129 [TBL] [Abstract][Full Text] [Related]
18. Avidity of IgG antibodies against mumps, parainfluenza 2 and Newcastle disease viruses after mumps infection. Lehtonen OP; Meurman OH J Virol Methods; 1986 Aug; 14(1):1-7. PubMed ID: 2429976 [TBL] [Abstract][Full Text] [Related]
19. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Nöjd J; Tecle T; Samuelsson A; Orvell C Vaccine; 2001 Feb; 19(13-14):1727-31. PubMed ID: 11166897 [TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Narita M; Yamada S; Matsuzono Y; Itakura O; Togashi T; Kikuta H Clin Diagn Lab Immunol; 1996 Mar; 3(2):211-5. PubMed ID: 8991638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]